SCOPE 2019

Tech is advancing, but uncertainty creates an ‘opposing effect’ to positive movement

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/z_wei)
(Image: Getty/z_wei)

Related tags: CRF Bracket, Technology, eConsent, eCOA

The industry has advanced to a point that should justify the financial investment in new technology, though uncertainty, and a lack of support, are hindering movement.

Jeff Lee, product lead for patient engagement and eConsent at CRF Bracket, is speaking this week at the 10th Annual Summit of Clinical Operations Executives (SCOPE) in Orlando, FL.

In his session, Lee will talk about three solution areas: eConsent, eCOA, and patient engagement. While the barriers for adoption of these differ somewhat, the top three are adequate budget within the overall study budget, clear value proposition, and regulatory considerations. 

“As an industry, we are enhancing our technologies so they can be delivered more efficiently,” ​said Lee. “We’re also seeing a gradual accumulation of case studies and journal articles demonstrating the positive impact of these technologies,”

Backed by these trends, Lee said the industry should have the validation to budget for technology appropriately. Still, the industry faces uncertainty as it pertains to the regulator's view of topics such as electronic signatures and Software as Medical Device (SaMD​) regulations. Lee noted it could also be quite simply, a lack of support.

“This creates an opposing effect to the positive movement in the other areas,”​ he said.

Challenges, changes, and continued adoption

Implementing eConsent does pose its own set of challenges, including the provisioning of single-use devices to sites, gaining regulatory acceptance of different forms of electronic signature, and handling complex studies with disparate consent documents.

However, these are modest challenges compared to the overall scheme of eClinical technologies, said Lee. And yet, the adoption of eConsent remains in the low single-digits. 

“This low adoption means that studies still struggle with protocol deviations due to poor protocol comprehensions, as well as critical regulator findings due to erroneous consenting activities, among other problems,”​ explained Lee.

Offered as a stand-alone solution, Lee said eConsent has limited opportunity to be adopted by studies moving forward.

“However, in the coming years, we will see eConsent delivered together with other solutions (like Patient Engagement, IRT, eCOA) such that it has a lower unique cost to the sponsor and therefore has a stronger ROI,”​ he said. “This will promote continued adoption to the point, within 5 years, eConsent will have surpassed where eCOA is today in terms of adoption.”

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars